Overview
Lupin Limited announced the launch of the United States Food and Drug Administration (FDA) approved mirabegron extended-release tablets, 25 mg in US markets.
Mirabegron Generic Counterpart
Mirabegron extended-release tablets, 25 mg is a generic equivalent of Myrbetriq extended-release tablets, 25 mg of Astellas Pharma Global Development, Inc.
Mirabegron: Annual sale
Mirabegron extended-release tablets, 25 mg had estimated annual sales of USD 1,019 million in the US (IQVIA MAT February 2024).
About Lupin
- Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
- The company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
